| Scrip Code | 543524 |
|---|---|
| NSE Symbol | RAINBOW |
| MSEI Symbol | NOTLISTED |
| ISIN | INE961O01016 |
| Name of company | Rainbow Childrens Medicare Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 13-11-2025 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 07-11-2025 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Second quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | The business of running multi-specialty pediatric and obstetrics and gynecology hospital. |
| Start date and time of board meeting | 13-11-2025 14:00:00 |
| End date and time of board meeting | 13-11-2025 16:00:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 09-02-2025 |
| Indicate Company website link for updated RPT policy of the Company | https://d31scedd5hpubp.cloudfront.net/investor_files/Policy_on_Materiality_and_Dealing_with_Related_Party_TransactionsFEB2025.pdf |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| As per results attached there are no default on loans and debt securities. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 40,849.60 | 74,324.40 | |
| Other income | 817.30 | 2,745.80 | |
| Total income | 41,666.90 | 77,070.20 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 5,609.30 | 10,004.30 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 0.00 | 0.00 |
| (d) | Employee benefit expense | 5,327.40 | 10,251.00 |
| (e) | Finance costs | 1,730.90 | 3,470.20 |
| (f) | Depreciation, depletion and amortisation expense | 3,318.20 | 6,577.50 |
| (f) | Other Expenses | ||
| 1 | Professional fees to doctors | 9,662.60 | 18,340.70 |
| 2 | Canteen expenses | 629.80 | 1,265.70 |
| 3 | Contract wages | 1,074.50 | 2,052.00 |
| 4 | Housekeeping expenses | 172.00 | 380.60 |
| 5 | Power and fuel | 655.20 | 1,345.10 |
| 6 | Lab and investigations | 391.30 | 787.90 |
| 7 | Repairs and maintenance | 765.30 | 1,514.20 |
| 8 | Rates and taxes | 421.30 | 860.60 |
| 9 | Business promotion and advertisement | 588.80 | 1,062.70 |
| 10 | Other Expenses | 1,480.30 | 2,435.70 |
| Total other expenses | 15,841.10 | 30,045.20 | |
| Total expenses | 31,826.90 | 60,348.20 | |
| 3 | Total profit before exceptional items and tax | 9,840.00 | 16,722.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 9,840.00 | 16,722.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 2,802.00 | 4,453.90 |
| 8 | Deferred tax | (278.70) | (220.60) |
| 9 | Total tax expenses | 2,523.30 | 4,233.30 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 7,316.70 | 12,488.70 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 7,316.70 | 12,488.70 |
| 17 | Other comprehensive income net of taxes | (5.40) | (10.80) |
| 18 | Total Comprehensive Income for the period | 7,311.30 | 12,477.90 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 10,155.90 | 10,155.90 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 7.2 | 12.3 | |
| Diluted earnings (loss) per share from continuing operations | 7.2 | 12.3 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 7.2 | 12.3 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 7.2 | 12.3 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1 The above statement of unaudited standalone financial results of Rainbow Childrens Medicare Limited the Company which have been prepared in accordance with Indian Accounting Standards Ind AS prescribed under section 133 of Companies Act 2013 the Act read with relevant rules issued thereunder other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India SEBI Listing Obligations and Disclosure Requirements Regulations 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 November 2025 The statutory auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon 2 The Company has allotted 7483 equity shares of Rs 10 each consequent to the exercise of the stock options by an eligible employee of the Company under the Rainbow Childrens Medicare Limited Employee Stock Unit Plan 2023 Stock Unit Plan 2023 The allotment has been approved by the Nomination and Remuneration committee on 12 August 2025 3 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025 the Company approved The Rainbow Childrens Medicare Limited Employee Stock Option Scheme 2025 ESOP 2025 in compliance with the SEBI Share Based Employee Benefits and Sweat Equity Regulations 2021 SEBI SBEB SE Regulations The ESOP 2025 is for issue of employee stock options to eligible employees which may result in an issuance of a maximum number of 1015000 Equity Shares Upon exercise and payment of the exercise price an option holder will be entitled to be allotted one equity share per employee stock option The Nomination and Remuneration Committee NRC of the Company in its meeting held on 13 November 2025 granted 5660 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 5660 equity shares having face value of Rs10 each fully paidup The Exercise price per stock option shall be determined at a discount of not more than 20 Percent on the latest available closing price of the Companys equity shares on the National Stock Exchange of India Limited being the stock exchange with the highest trading volume as on 13 November 2025 ie the trading day immediately preceding the date on which the grant of options was approved by the NRC The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting 4 Pursuant to Securities Subscription Agreement SSA and Shareholders Agreement SHA dated 28 June 2025 the Company has acquired 76 Percent of equity share capital and 100 Percent of NonConvertible Redeemable Preference shares of Ms Prashanthi Medicare Private Limited Prashanthi Hospital for an aggregate cash consideration of Rs 326 million Consequent to this acquisition Prashanthi Hospital became a subsidiary of the Company with effect from 01 July 2025 upon satisfactory completion of the closing conditions under the SSA 5 Pursuant to Securities Subscription Agreement SSA and Shareholders Agreement SHA dated 11 August 2025 the Company has acquired 76 Percent of equity share capital and 100 Percent of NonConvertible Redeemable Preference shares of Ms Pratiksha Women & Child Care Hospital Private Limited Pratiksha Hospital for an aggregate cash consideration of Rs 1710 million Consequent to this acquisition Pratiksha Hospital became a subsidiary of the Company with effect from 18 August 2025 upon satisfactory completion of the closing conditions under the SSA 6 The Company is principally engaged in a single business segment viz rendering medical and healthcare services Further the business operation of the Company are concentrated in India and hence the Company is considered to operate only in one geographical segment 7 The standalone financial results for the quarter and year to date ended 30 September 2025 are available on the BSE Limited website URL wwwbseindiacom the National Stock Exchange of India Limited website URL wwwnseindiacom and on the Companys website URL wwwrainbowhospitalsin |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 30-09-2025 | |
| Whether results are audited or unaudited | Unaudited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 1,34,009.40 | |
| Capital work-in-progress | 5,181.30 | |
| Investment property | 0.00 | |
| Goodwill | 0.00 | |
| Other intangible assets | 977.50 | |
| Intangible assets under development | 169.80 | |
| Biological assets other than bearer plants | 0.00 | |
| Investments accounted for using equity method | 0.00 | |
| Non-current financial assets | ||
| Non-current investments | 21,769.90 | |
| Trade receivables, non-current | 0.00 | |
| Loans, non-current | 6,228.60 | |
| Other non-current financial assets | 2,957.60 | |
| Total non-current financial assets | 30,956.10 | |
| Deferred tax assets (net) | 3,083.50 | |
| Other non-current assets | 4,757.40 | |
| Total non-current assets | 1,79,135.00 | |
| 2 | Current assets | |
| Inventories | 3,042.60 | |
| Current financial asset | ||
| Current investments | 38,802.90 | |
| Trade receivables, current | 10,772.00 | |
| Cash and cash equivalents | 1,620.80 | |
| Bank balance other than cash and cash equivalents | 2.00 | |
| Loans, current | 573.60 | |
| Other current financial assets | 10,888.60 | |
| Total current financial assets | 62,659.90 | |
| Current tax assets (net) | 998.50 | |
| Other current assets | 1,992.40 | |
| Total current assets | 68,693.40 | |
| 3 | Non-current assets classified as held for sale | 0.00 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 |
| Total assets | 2,47,828.40 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 10,155.90 | |
| Other equity | 1,48,195.90 | |
| Total equity attributable to owners of parent | 1,58,351.80 | |
| Non controlling interest | ||
| Total equity | 1,58,351.80 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 0.00 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | |
| Total Trade payable | 0.00 | |
| Other non-current financial liabilities | 70,538.20 | |
| Total non-current financial liabilities | 70,538.20 | |
| Provisions, non-current | 1,095.20 | |
| Deferred tax liabilities (net) | 0.00 | |
| Deferred government grants, Non-current | 0.00 | |
| Other non-current liabilities | 0.00 | |
| Total non-current liabilities | 71,633.40 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 0.00 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 1,063.30 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 10,219.50 | |
| Total Trade payable | 11,282.80 | |
| Other current financial liabilities | 4,171.40 | |
| Total current financial liabilities | 15,454.20 | |
| Other current liabilities | 1,441.60 | |
| Provisions, current | 652.60 | |
| Current tax liabilities (Net) | 294.80 | |
| Deferred government grants, Current | 0.00 | |
| Total current liabilities | 17,843.20 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0.00 |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 |
| Total liabilities | 89,476.60 | |
| Total equity and liabilites | 2,47,828.40 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-07-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 30-09-2025 | 30-09-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Re-measurement (loss) / gain on defined benefit obligation | -720000 | -1440000 |
| Total Amount of items that will not be reclassified to profit and loss | (7.20) | (14.40) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (1.80) | (3.60) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (5.40) | (10.80) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 30-09-2025 | ||||
| C | Whether results are audited or unaudited | Unaudited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 16,722.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 3,470.20 | |||||
| Adjustments for decrease (increase) in inventories | (768.40) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (2,687.80) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | 0.00 | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | (216.80) | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | 2,694.90 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 0.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 6,577.50 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 138.30 | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 292.30 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 0.00 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 617.80 | |||||
| Adjustments for share-based payments | 65.40 | |||||
| Adjustments for fair value losses (gains) | (180.20) | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (1,827.00) | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | (356.60) | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 6,584.00 | |||||
| Net cash flows from (used in) operations | 23,306.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 4,159.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 19,147.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 15,481.20 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 4,878.80 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 127.70 | |||||
| Purchase of property, plant and equipment | 9,273.70 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 300.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 20.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 171.40 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 17,685.40 | |||||
| Net cash flows from (used in) investing activities | (11,929.20) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.70 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 0.00 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 4,240.20 | |||||
| Dividends paid | 3,046.50 | |||||
| Interest paid | 0.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (7,286.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | (68.20) | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | (68.20) | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 1,689.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 1,620.80 | |||||
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Rainbow Children's Medicare Limited | Mr. Ramadhara Naidu Kancharla | Brother of Key Managerial Personnel (KMP) | Purchase of goods or services | 60.00 | NA | 25.00 | 5.00 | 0.00 | Textual Information(1) | |||||||||||||||
| 2 | Rainbow Children's Medicare Limited | Mr. Ramadhara Naidu Kancharla | Brother of Key Managerial Personnel (KMP) | Any other transaction | Reimbursement of expenses | 100.00 | Approved by Audit Committee | 3.60 | 0.00 | 0.00 | |||||||||||||||
| 3 | Rainbow Children's Medicare Limited | Ravindranath GE Medical Associates Private Limited | Enterprises where key managerial personnel along with their relatives exercise significant influence | Purchase of goods or services | 100.00 | Approved by Audit Committee | 2.50 | 0.00 | 0.00 | ||||||||||||||||
| 4 | Rainbow Children's Medicare Limited | Rainbow Speciality Hospitals Private Limited | Subsidiary | Purchase of goods or services | 100.00 | Approved by Audit Committee | 3.60 | 0.00 | 0.00 | ||||||||||||||||
| 5 | Rainbow Children's Medicare Limited | Rainbow Speciality Hospitals Private Limited | Subsidiary | Any other transaction | Medical Service fee paid | 100.00 | Approved by Audit Committee | 10.30 | 0.00 | 0.00 | |||||||||||||||
| 6 | Rainbow Children's Medicare Limited | Rainbow Speciality Hospitals Private Limited | Subsidiary | Any other transaction | Rent paid | 42.00 | Approved by Audit Committee | 21.00 | 0.00 | 0.00 | |||||||||||||||
| 7 | Rainbow Children's Medicare Limited | Rainbow Speciality Hospitals Private Limited | Subsidiary | Any other transaction | Reimbursement of expenses | 100.00 | Approved by Audit Committee | 0.00 | 0.00 | 0.00 | |||||||||||||||
| 8 | Rainbow Children's Medicare Limited | Rainbow Speciality Hospitals Private Limited | Subsidiary | Sale of goods or services | 100.00 | Approved by Audit Committee | 40.20 | 0.00 | 0.00 | ||||||||||||||||
| 9 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Inter-corporate deposit | 500.00 | Approved by Audit Committee | 80.00 | 20.00 | 100.00 | ||||||||||||||||
| 10 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Any other transaction | Accrued Interest on Inter Corporate Deposits | 47.50 | Approved by Audit Committee | 2.20 | 2.60 | 1.80 | |||||||||||||||
| 11 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Any other transaction | Rent Received | 50.00 | Approved by Audit Committee | 11.00 | 1.90 | 1.90 | |||||||||||||||
| 12 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Any other transaction | Security Deposit | 0.70 | Approved by Audit Committee | 0.00 | 0.70 | 0.70 | |||||||||||||||
| 13 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Purchase of goods or services | 1,500.00 | Approved by Audit Committee | 141.90 | 17.30 | 105.90 | ||||||||||||||||
| 14 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Sale of goods or services | 1,000.00 | Approved by Audit Committee | 70.20 | 343.50 | 423.30 | ||||||||||||||||
| 15 | Rainbow Children's Medicare Limited | Rainbow CRO Private Limited | Wholly Owned Subsidiary | Sale of goods or services | 10.00 | Approved by Audit Committee | 0.10 | 0.40 | 0.40 | ||||||||||||||||
| 16 | Rainbow Children's Medicare Limited | Rainbow Children's Foundation | Enterprises where key managerial personnel along with their relatives exercise significant influence | Sale of goods or services | 100.00 | Approved by Audit Committee | 25.10 | 20.00 | 1.00 | ||||||||||||||||
| 17 | Rainbow Children's Medicare Limited | Unimed Healthcare Private Limited | Enterprises where relative of key managerial personnel is a member | Any other transaction | Security Deposit | 300.00 | Approved by Audit Committee | 0.00 | 300.00 | 300.00 | |||||||||||||||
| 18 | Rainbow Children's Medicare Limited | Unimed Healthcare Private Limited | Enterprises where relative of key managerial personnel is a member | Any other transaction | Reimbursement of expenses | 250.00 | Approved by Audit Committee | 102.40 | 0.00 | 0.00 | |||||||||||||||
| 19 | Rainbow Children's Medicare Limited | Unimed Healthcare Private Limited | Enterprises where relative of key managerial personnel is a member | Sale of goods or services | 200.00 | Approved by Audit Committee | 3.60 | 7.20 | 10.80 | ||||||||||||||||
| 20 | Rainbow Children's Medicare Limited | Unimed Healthcare Private Limited | Enterprises where relative of key managerial personnel is a member | Purchase of goods or services | 500.00 | Approved by Audit Committee | 154.50 | 22.10 | 24.60 | ||||||||||||||||
| 21 | Rainbow Children's Medicare Limited | Unimed Healthcare Private Limited | Enterprises where relative of key managerial personnel is a member | Any other transaction | Rent paid | 700.00 | Approved by Audit Committee | 272.20 | 49.00 | 49.00 | |||||||||||||||
| 22 | Rainbow Children's Medicare Limited | Rainbow Children's Hospital Foundation | Enterprises where key managerial personnel along with their relatives exercise significant influence | Any other transaction | CSR spent on behalf of Rainbow Children's Medicare Limited | 1,000.00 | Approved by Audit Committee | 10.00 | 0.00 | 0.00 | |||||||||||||||
| 23 | Rainbow Children's Medicare Limited | Dr. Ramesh Kancharla | Chairman and Managing Director | Remuneration | NA | 54.20 | 0.00 | 0.00 | Textual Information(2) | ||||||||||||||||
| 24 | Rainbow Children's Medicare Limited | Dr. Ramesh Kancharla | Chairman and Managing Director | Any other transaction | Travel Advance | NA | 11.00 | 26.50 | 29.10 | Textual Information(3) | |||||||||||||||
| 25 | Rainbow Children's Medicare Limited | Dr. Dinesh Kumar Chirla | Whole Time Director | Purchase of goods or services | 600.00 | Appoved by the Audit Committee | 52.10 | 28.10 | 0.00 | ||||||||||||||||
| 26 | Rainbow Children's Medicare Limited | Dr. Adarsh Kancharla | Non-Executive Director | Any other transaction | Board and Committee Meeting Sitting Fee | NA | 2.50 | 0.00 | 0.00 | Textual Information(4) | |||||||||||||||
| 27 | Rainbow Children's Medicare Limited | Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Purchase of goods or services | 200.00 | Approved by Audit Committee | 0.00 | 10.20 | 0.00 | ||||||||||||||||
| 28 | Rainbow Children's Medicare Limited | Dr. Sai Aishwarya Chirla | Relative of KMP | Purchase of goods or services | 9.60 | Approved by Audit Committee | 3.90 | 0.00 | 0.00 | ||||||||||||||||
| 29 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Any other transaction | Investment in Share Capital of Subsidiary | NA | 2,485.20 | 0.00 | 2,485.20 | Textual Information(5) | |||||||||||||||
| 30 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Any other transaction | Investment in NCRPS (Equity Component) | NA | 259.50 | 0.00 | 259.50 | Textual Information(6) | |||||||||||||||
| 31 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Any other transaction | Investment in NCRPS (Loan Component) | NA | 526.20 | 0.00 | 526.20 | Textual Information(7) | |||||||||||||||
| 32 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Interest received | Approved by Audit Committee | 1.80 | 0.00 | 1.80 | |||||||||||||||||
| 33 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Inter-corporate deposit | 500.00 | Approved by Audit Committee | 200.00 | 0.00 | 200.00 | ||||||||||||||||
| 34 | Rainbow Children's Medicare Limited | Prashanthi Medicare Private Limited | Subsidiary | Sale of goods or services | 500.00 | Approved by Audit Committee | 9.90 | 0.00 | 0.00 | ||||||||||||||||
| 35 | Rainbow Children's Medicare Limited | Pratiksha Women & Child Care Hospital Private Limited | Subsidiary | Any other transaction | Investment in Share Capital of Subsidiary | NA | 12,996.00 | 0.00 | 12,996.00 | Textual Information(8) | |||||||||||||||
| 36 | Rainbow Children's Medicare Limited | Pratiksha Women & Child Care Hospital Private Limited | Subsidiary | Any other transaction | Investment in NCRPS (Equity Component) | NA | 1,374.70 | 0.00 | 1,374.70 | Textual Information(9) | |||||||||||||||
| 37 | Rainbow Children's Medicare Limited | Pratiksha Women & Child Care Hospital Private Limited | Subsidiary | Any other transaction | Investment in NCRPS (Loan Component) | NA | 2,758.30 | 0.00 | 2,758.30 | Textual Information(10) | |||||||||||||||
| 38 | Prashanthi Medicare Private Limited | Rosewalk Healthcare Private Limited | Enterprises where key managerial personnel along with their relatives exercise significant influence | Any other transaction | Rent | 0.60 | Approved by Audit Committee | 0.10 | 0.00 | 0.10 | |||||||||||||||
| Total value of transaction during the reporting period | 21,714.80 | ||||||||||||||||||||||||
| Textual Information(1) | This was approved by the Board of Directors |
| Textual Information(2) | This was approved by the Board of Directors and Shareholders of the Company |
| Textual Information(3) | This was approved by the Board of Directors and Shareholders of the Company |
| Textual Information(4) | This was approved by the Board of Directors |
| Textual Information(5) | This was approved by the Board of Directors |
| Textual Information(6) | This was approved by the Board of Directors |
| Textual Information(7) | This was approved by the Board of Directors |
| Textual Information(8) | This was approved by the Board of Directors |
| Textual Information(9) | This was approved by the Board of Directors |
| Textual Information(10) | This was approved by the Board of Directors |